Seres Therapeutics outlines global Phase II SER-155 trial with 248-patient enrollment amid partnership talks Seres Therapeutics outlines global Phase II SER-155 trial with 248-patient enrollment amid partnership talks Post ContentmcrbRead More You might also be interested in reading PIMCO Dynamic Income Fund declares $0.2205 dividend. August 7, 2025 In Mainstream ← Previous post Next post →